Immuneering
IMRXImmuneering is developing a new class of cancer medicines called Deep Cyclic Inhibitors, which employ a pulsed dosing strategy to overcome the limitations of traditional continuous inhibition. The company's lead programs target the MAPK pathway, a critical driver in many cancers, with the goal of delivering more durable responses and better tolerability. Immuneering is a publicly traded company (NASDAQ: IMRX) with a seasoned leadership team and a clear focus on transforming cancer care through innovative treatment paradigms.
IMRX · Stock Price
Historical price data
AI Company Overview
Immuneering is developing a new class of cancer medicines called Deep Cyclic Inhibitors, which employ a pulsed dosing strategy to overcome the limitations of traditional continuous inhibition. The company's lead programs target the MAPK pathway, a critical driver in many cancers, with the goal of delivering more durable responses and better tolerability. Immuneering is a publicly traded company (NASDAQ: IMRX) with a seasoned leadership team and a clear focus on transforming cancer care through innovative treatment paradigms.
Technology Platform
Deep Cyclic Inhibitor platform, a novel dosing paradigm using rhythmic, pulsed inhibition to outpace cancer's adaptive resistance mechanisms, initially applied to the MAPK pathway.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| IMM-1-104 Monotherapy (Treatment Group A) + IMM-1-104 + modi... | Advanced Solid Tumor | Phase 1/2 | |
| IMM-6-415 | Advanced Solid Tumor (Phase 1) | Phase 1/2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Competes with major pharma and biotech companies developing continuous inhibitors for the MAPK pathway (e.g., Amgen, BMS, Pfizer, Novartis). Immuneering's core differentiation is its cyclic dosing strategy aimed at overcoming adaptive resistance and improving tolerability, rather than just a new molecular entity.